Skip to Main Content

WASHINGTON — A judge’s decision to suspend the Food and Drug Administration’s approval of an abortion pill could have massive impacts for the pharmaceutical industry, but its largest lobbying association is staying on the sidelines.

PhRMA, which is the top-spending lobbying group in the health care sector and is known to be litigious itself, still hasn’t put out a press release on the decision made by a judge in Texas on Friday — despite the possibility that the decision could destabilize the sanctity of the FDA approval process entirely.


Instead, PhRMA is sending a restrained statement to reporters upon request:

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.